A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-21

Study Completion Date

2021-10-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is open to adults with mild to moderate symptoms of COVID-19 (coronavirus disease). The purpose of this study is to find out whether a medicine called BI 767551 helps people with COVID-19. BI 767551 is an antibody against the coronavirus.

The study has 2 parts.

Part 1 wants to find out the best dose of BI 767551 given as infusion into a vein. It also tests how BI 767551 is taken up by the body when taken via an inhaler. Participants are put into 4 groups by chance. Participants get BI 767551 or placebo once.

* 1 group gets a high dose of BI 767551 as an infusion into a vein
* 1 group gets a low dose of BI 767551 as an infusion into a vein
* 1 group gets BI 767551 via an inhaler
* 1 group gets placebo both as an infusion into a vein and via an inhaler

The placebo infusion and inhaler look like the BI 767551 infusion and inhaler but do not contain any medicine.

Doctors check how BI 767551 reduces the amount of coronavirus. Once the best dose of BI 767551 is found, part 2 of the study tests BI 767551 in a larger group of people. Also, in part 2, the participants get BI 767551 or placebo as an infusion into a vein once. In this part, doctors will check how many people need to be treated in a hospital or die. The results will be compared between the groups.

For each part, participants are in the study for about 13 weeks. During this time, they visit the study site about 8 times and get about 3 remote visits.

The doctors also regularly check participants' health and take note of any unwanted effects of BI 767551.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

NCT04894474

COVID-19

WITHDRAWN PHASE2/PHASE3

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898

Covid19

COMPLETED PHASE2

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

NCT04427501

COVID-19

COMPLETED PHASE2/PHASE3

Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients

NCT05173441

COVID-19

UNKNOWN PHASE2

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

NCT04532294

Covid19

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This trial consists of two phases:

Exploratory Phase II:

Randomised, double-blind, placebo controlled, doubledummy,Phase II, parallel group design comparing different doses and modes of administration of BI 767551 to placebo.

Confirmatory Phase III:

Randomised, double-blind, placebo-controlled, parallel group, Phase III comparing BI 767551 to placebo.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase II, Arm 1: Placebo intravenous (i.v.) + placebo inhaled

Single dose of sterile normal saline (NaCl 0.9%) used as placebo for intravenous (i.v.) was administered as intravenous infusion over a period of 60 minutes plus a single inhaled of solvent for dilution of BI 767551 used as placebo for inhalation administered via inhalation through a mouthpiece (Aerogen® Ultra) using a mesh nebulizer (Aerogen® Solo) on Day 1, followed by a 90-day follow-up period. The inhalation procedure was to start approximately 25 min after the start of infusion.

Group Type PLACEBO_COMPARATOR

Placebo intravenous

Intervention Type DRUG

Placebo intravenous

Placebo inhaled

Intervention Type DRUG

Placebo inhaled

Phase II, Arm 2: BI 767551 10 milligrams (mg)/kilogram (kg) intravenous (i.v.) + placebo inhaled

Group Type EXPERIMENTAL

BI 767551 intravenous

Intervention Type DRUG

BI 767551 intravenous

Placebo inhaled

Intervention Type DRUG

Placebo inhaled

Phase II, Arm 3: BI 767551 40 mg/kg intravenous (i.v.) + placebo inhaled

Group Type EXPERIMENTAL

BI 767551 intravenous

Intervention Type DRUG

BI 767551 intravenous

Placebo inhaled

Intervention Type DRUG

Placebo inhaled

Phase II, Arm 4: Placebo intravenous (i.v.) + BI 767551 250 mg inhaled

Single dose of sterile normal saline (NaCl 0.9%) used as placebo for intravenous (i.v.) was administered as intravenous infusion over a period of 60 minutes plus a single inhaled of 250 milligrams (mg) of BI 767551 administered via inhalation through a mouthpiece (Aerogen® Ultra) using a mesh nebulizer (Aerogen® Solo) on Day 1, followed by a 90-day follow-up period. The inhalation procedure was to start approximately 25 min after the start of infusion.

Group Type EXPERIMENTAL

BI 767551 inhaled

Intervention Type DRUG

BI 767551 inhaled

Placebo intravenous

Intervention Type DRUG

Placebo intravenous

Phase III, Arm 1: BI 767551 (medium or high dose infusion) or low dose inhalation

Group Type EXPERIMENTAL

BI 767551 intravenous

Intervention Type DRUG

BI 767551 intravenous

Phase III, Arm 2: Placebo

Group Type PLACEBO_COMPARATOR

Placebo intravenous

Intervention Type DRUG

Placebo intravenous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 767551 intravenous

Intervention Type DRUG

BI 767551 inhaled

Intervention Type DRUG

Placebo intravenous

Intervention Type DRUG

Placebo inhaled

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years old, males and females
* Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
* Documentation of laboratory-confirmed Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (nasopharyngeal (NP) or nasal swab or saliva) collected no more than 72 hours prior to start of treatment
* Patients experienced mild to moderate Coronavirus Disease 2019 (COVID-19)-related symptoms or measured fever for no more than 5 days prior to start of treatment where symptoms are defined by fever, feeling feverish, fatigue, cough, shortness of breath at rest or during activity, sore throat, body pain or muscle pain/ aches, chills, headache, nasal obstruction or congestion, loss of smell or taste, nausea, diarrhea, vomiting, or dysgeusia
* One or more of the following signs/symptoms present on day of start of treatment: fever, feeling feverish, fatigue, cough, shortness of breath at rest or during activity, sore throat, body pain or muscle pain/ aches, chills, headache, nasal obstruction or congestion, loss of smell or taste, nausea, diarrhea, vomiting, or dysgeusia
* Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly

Exclusion Criteria

* Body weight of less than 40 kg
* Severe or critical COVID-19 including at least one of

* Oxygen saturation (SpO2) ≤ 93 % on room air or on their usual level of oxygen supplementation in case of chronic oxygen use
* Ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) \< 300 (in case arterial blood sample was taken)
* History of hospitalization for COVID-19
* Current or imminent need for hospitalization or immediate medical attention in the clinical opinion of the site investigator. Does not include patients hospitalized for isolation only
* Receipt of intravenous immunoglobulin within 12 weeks prior to Visit 2
* Receipt of COVID-19 convalescent plasma treatment at any time prior to Visit 2
* Receipt of any SARS-CoV-2 monoclonal antibody treatment at any time prior to Visit 2
* Receipt of SARS-CoV-2 vaccine at any time prior to Visit 2
* Receipt of an investigational product for COVID-19 within 5 half-lives prior to Visit 2

Exclusion criterion phase III only:

\- Previous enrolment in this trial. Patients participating in Phase II are not eligible for Phase III. Re-screening is allowed once, for repeat of Quantitative Reverse Transcription Polymerase chain reaction (RT-qPCR) or antigen SARS-CoV-2 test, if required. The test method used for initial screening (RT-qPCR or antigen) should be used for re-screening.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No